Oncternal Therapeutics announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ONCT:
- Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Oncternal Therapeutics announces Prostate Cancer Scientific Advisory Board
- Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
- Oncternal Therapeutics reports Q2 EPS ,(15c) consensus (16c)